Kiniksa Pharmaceuticals International Q3 2026 Earnings Report

Kiniksa Pharmaceuticals International EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.39
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Kiniksa Pharmaceuticals International Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $259.65 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Kiniksa Pharmaceuticals International Announcement Details

• Quarter: Q3 2026
• Date: 10/27/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, October 27, 2026
• Conference Call Time: 8:30AM ET

Kiniksa Pharmaceuticals International (NASDAQ:KNSA), Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for patients with debilitating diseases, including conditions driven by immune-system and inflammatory responses. The company’s strategy centers on targeted medicines intended to address significant unmet medical needs in specialty markets.

Kiniksa’s primary commercial product is ARCALYST (rilonacept), an interleukin-1 blocker. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children age 12 and older. It is also approved for the treatment of cryopyrin-associated periodic syndromes, a group of rare autoinflammatory disorders.

Kiniksa was founded in 2015 and operates as part of the broader Kiniksa Pharmaceuticals organization, which is headquartered in Bermuda with operations in the United States. Sanj K. Patel is the company’s co-founder, chairman and chief executive officer. The company’s commercial activities are primarily focused on specialty and rare-disease markets, supported by research and development programs in immunology and inflammation.